Armatus Unveils Scalable Potency Assay Platform to Advance Next-Generation Gene Silencing Therapies
Armatus Bio, a late-preclinical biotechnology company focused on developing vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of new research in Molecular Therapy Advances detailing the development of a novel in vitro potency assay platform. This innovation is designed to accelerate the advancement of gene-silencing therapies for serious and often rare neuromuscular diseases, including Facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease type 1A.
The announcement highlights a critical step forward in the development of RNAi-based therapeutics, which have gained increasing attention as a precise and potentially transformative approach for treating genetically driven diseases. By selectively silencing disease-causing genes, RNAi therapies aim to address conditions at their molecular root. When combined with adeno-associated virus (AAV) vectors for delivery, these therapies offer the potential for long-lasting effects from a single administration. However, despite their promise, the development of such therapies has faced a significant technical hurdle: the lack of reliable, standardized assays to measure potency.
Potency assays are essential tools in drug development, used to evaluate the biological activity of a therapeutic product. For gene therapies, these assays help ensure that each manufactured batch performs consistently and meets quality standards required for regulatory approval. In the context of RNAi therapies delivered via AAV vectors, developing such assays has proven particularly challenging due to variability in transduction efficiency, gene expression, and cellular responses. These challenges have slowed progress in bringing promising therapies from the laboratory to clinical trials.
To address this bottleneck, researchers affiliated with Armatus Bio have developed a robust and scalable in vitro assay platform that enables precise measurement of gene-silencing activity. The system is based on engineered human cell lines specifically designed to overcome the limitations of traditional AAV testing methods. By incorporating the universal AAV receptor (AAVR) into these cells, the researchers enhanced the efficiency and consistency of viral vector entry, ensuring more reliable experimental conditions.
In addition, the platform utilizes a luciferase-based reporter system linked to disease-relevant gene sequences. This allows researchers to quantitatively measure the extent of gene silencing by detecting changes in luminescence, providing a clear and dose-dependent readout of therapeutic activity. The combination of these elements results in a highly sensitive and reproducible assay that can be applied across different gene targets and therapeutic constructs.
According to Scott Harper, PhD, Principal Investigator at the Nationwide Children’s Hospital Center for Gene Therapy and Chief Scientific Advisor to Armatus Bio, the goal was to create a system that could be used throughout the entire development lifecycle. He explained that the team leveraged its deep understanding of engineered microRNA mechanisms to design an assay that is not only scientifically rigorous but also practical for real-world application. The resulting platform is intended to be implemented early in development and scaled seamlessly through clinical and commercial stages.
The study demonstrated several key advantages of the new assay platform. First, it provides quantifiable, dose-dependent measurements of gene-silencing activity, enabling researchers to accurately assess the potency of RNAi therapeutics. This is particularly important for determining optimal dosing and ensuring consistent performance across manufacturing batches. Second, the platform simplifies assay development and product release testing, reducing the time and resources required to bring new therapies to market. Finally, its versatility allows it to be applied to a wide range of gene targets, extending its utility beyond the specific diseases studied.
The implications of this development are significant for the broader field of gene therapy. By providing a reliable method for assessing potency, the platform addresses a key regulatory requirement and facilitates the progression of therapies through preclinical and clinical stages. This, in turn, can shorten development timelines and increase the likelihood of successful regulatory approval.
Rachel Salzman, DVM, Chief Executive Officer of Armatus Bio, emphasized the strategic importance of the innovation. She noted that the ability to generate consistent, quantifiable data on critical quality attributes—such as lot release, stability, and manufacturing comparability—will enhance both development efficiency and regulatory readiness. According to Salzman, the platform effectively removes a common obstacle in early-stage gene therapy development, paving the way for faster clinical translation.
The impact of this advancement is particularly relevant for rare diseases, where patient populations are small and the need for effective treatments is urgent. Conditions such as FSHD and CMT1A are characterized by progressive muscle weakness and neurological impairment, with limited therapeutic options currently available. By enabling more efficient development of RNAi therapies targeting these diseases, the new assay platform could help bring innovative treatments to patients more quickly.
Beyond neuromuscular disorders, the platform’s adaptability suggests potential applications across a broad spectrum of genetic diseases. As RNAi and AAV-based therapies continue to evolve, having a standardized and scalable method for evaluating potency will be essential for supporting the growth of the field. The ability to apply the same assay framework to multiple targets and indications could streamline development pipelines and reduce redundancy, further accelerating innovation.
The publication of this research in a peer-reviewed journal underscores its scientific credibility and relevance to the broader research community. It also reflects Armatus Bio’s commitment to advancing not only its own therapeutic programs but also the foundational technologies that support the development of gene-based medicines.
Looking ahead, the company is expected to integrate this assay platform into its ongoing development programs, using it to support the advancement of its pipeline of vectorized RNAi therapies. As these programs move closer to clinical evaluation, the availability of a robust potency assay will be critical for meeting regulatory expectations and ensuring patient safety.
In summary, Armatus Bio’s newly published research represents a meaningful contribution to the field of gene therapy. By addressing a longstanding challenge in potency testing, the company has developed a platform that enhances the reliability, scalability, and efficiency of RNAi therapeutic development. As the industry continues to push the boundaries of precision medicine, innovations like this will play a vital role in translating scientific breakthroughs into real-world treatments for patients with serious and underserved conditions.
About Armatus
Armatus Bio is a late-preclinical stage, privately held biotech innovator developing advanced medicines that leverage vectorized RNAi (RNA interference). Armatus’ uniquely specific, engineered microRNAs are noncoding RNAs responsible for regulating gene expression by mirroring innate cellular biogenesis processes without altering the underlying genetic make-up.
The company’s two lead assets are designed to target neuromuscular disorders: TVR110 for Charcot-Marie-Tooth disease type 1A (CMT1A), and ARM-201 for Facioscapulohumeral Muscular Dystrophy (FSHD), which together affect more than 225,000 people in the U.S. and European Union. In preclinical studies, these investigational drugs demonstrated robust signals of target engagement and biomarker improvement, and both are advancing toward the clinic.
